First Time Loading...

CogState Ltd
ASX:CGS

Watchlist Manager
CogState Ltd Logo
CogState Ltd
ASX:CGS
Watchlist
Price: 1.395 AUD 1.82% Market Closed
Updated: Apr 30, 2024
Section:
 

Relative Value

The Relative Value of one CGS stock under the Base Case scenario is 2.784 AUD. Compared to the current market price of 1.395 AUD, CogState Ltd is Undervalued by 50%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CGS Relative Value
Base Case
2.784 AUD
Undervaluation 50%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.8
P/S
P/S
Price to Sales
3.8
vs History
65
vs Industry
33
Median 3Y
4.5
Median 5Y
4.2
Industry
2.4
Forward
3.6
More Details
28.5
P/E
P/E
Price to Earnings
28.5
vs History
47
vs Industry
20
Median 3Y
41.8
Median 5Y
27.2
Industry
23.2
Forward
33.6
More Details
320.1
P/OCF
P/OCF
Price to OCF
320.1
vs History
1
vs Industry
0
Median 3Y
24.7
Median 5Y
21.3
Industry
15.5
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
13
Median 3Y
23.9
Median 5Y
-6.3
Industry
23.5
More Details
4.1
P/B
P/B
Price to Book Value
4.1
vs History
66
vs Industry
22
Median 3Y
6.9
Median 5Y
5.3
Industry
2.2
More Details
3.2
EV/S
EV/S
Enterprise Value to Sales
3.2
vs History
65
vs Industry
36
Median 3Y
3.9
Median 5Y
3.5
Industry
2.5
Forward
3.1
More Details
5.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.8
vs History
65
vs Industry
40
Median 3Y
7.6
Median 5Y
6.9
Industry
5.2
More Details
26
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
26
vs History
38
vs Industry
12
Median 3Y
30
Median 5Y
19.3
Industry
12.5
Forward
15.4
More Details
26
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
26
vs History
38
vs Industry
18
Median 3Y
30
Median 5Y
19.3
Industry
17.2
Forward
22.3
More Details
269.5
EV/OCF
EV/OCF
Enterprise Value to OCF
269.5
vs History
1
vs Industry
1
Median 3Y
21.6
Median 5Y
17.8
Industry
15.1
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
17
Median 3Y
20.7
Median 5Y
-5.2
Industry
19.7
More Details
5.7
EV/IC
EV/IC
Enterprise Value to IC
5.7
vs History
63
vs Industry
15
Median 3Y
8.2
Median 5Y
6.7
Industry
2
More Details

Multiples Across Competitors

CGS Competitors Multiples
CogState Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
CogState Ltd
ASX:CGS
239.1m AUD 3.8 28.5 26 26
US
Veeva Systems Inc
NYSE:VEEV
32.5B USD 13.8 61.8 61.6 66.3
US
Cerner Corp
NASDAQ:CERN
27.9B USD 4.8 47.3 19.6 38.6
US
Change Healthcare Inc
NASDAQ:CHNG
9B USD 2.6 -116.8 16.5 111.6
JP
M3 Inc
TSE:2413
1.3T JPY 5.4 27.5 14.6 16.4
AU
Pro Medicus Ltd
ASX:PME
11.7B AUD 79.8 167.3 115 115
US
Inspire Medical Systems Inc
NYSE:INSP
7.2B USD 11.5 -340.4 -180.1 -167.4
US
Doximity Inc
NYSE:DOCS
4.5B USD 9.6 32.8 22 23.4
SE
Sectra AB
STO:SECT B
42.9B SEK 26.2 101 -66.5 -66.5
US
Evolent Health Inc
NYSE:EVH
3.2B USD 1.6 -22.3 26.2 279.1
US
Goodrx Holdings Inc
NASDAQ:GDRX
2.8B USD 3.8 -317.7 33.9 -110.7
P/E Multiple
Earnings Growth
AU
CogState Ltd
ASX:CGS
Average P/E: 66.6
28.5
235%
US
Veeva Systems Inc
NYSE:VEEV
61.8
139%
US
Cerner Corp
NASDAQ:CERN
47.3
N/A
US
Change Healthcare Inc
NASDAQ:CHNG
Negative Multiple: -116.8 N/A
JP
M3 Inc
TSE:2413
27.5
26%
AU
Pro Medicus Ltd
ASX:PME
167.3
119%
US
Inspire Medical Systems Inc
NYSE:INSP
Negative Multiple: -340.4 N/A
US
Doximity Inc
NYSE:DOCS
32.8
79%
SE
Sectra AB
STO:SECT B
101
56%
US
Evolent Health Inc
NYSE:EVH
Negative Multiple: -22.3 N/A
US
Goodrx Holdings Inc
NASDAQ:GDRX
Negative Multiple: -317.7 N/A
EV/EBITDA Multiple
EBITDA Growth
AU
CogState Ltd
ASX:CGS
Average EV/EBITDA: 37.3
26
511%
US
Veeva Systems Inc
NYSE:VEEV
61.6
221%
US
Cerner Corp
NASDAQ:CERN
19.6
N/A
US
Change Healthcare Inc
NASDAQ:CHNG
16.5
N/A
JP
M3 Inc
TSE:2413
14.6
24%
AU
Pro Medicus Ltd
ASX:PME
115
124%
US
Inspire Medical Systems Inc
NYSE:INSP
Negative Multiple: -180.1 N/A
US
Doximity Inc
NYSE:DOCS
22
103%
SE
Sectra AB
STO:SECT B
Negative Multiple: -66.5 N/A
US
Evolent Health Inc
NYSE:EVH
26.2
194%
US
Goodrx Holdings Inc
NASDAQ:GDRX
33.9
305%
EV/EBIT Multiple
EBIT Growth
AU
CogState Ltd
ASX:CGS
Average EV/EBIT: 84.6
26
401%
US
Veeva Systems Inc
NYSE:VEEV
66.3
238%
US
Cerner Corp
NASDAQ:CERN
38.6
N/A
US
Change Healthcare Inc
NASDAQ:CHNG
111.6
N/A
JP
M3 Inc
TSE:2413
16.4
N/A
AU
Pro Medicus Ltd
ASX:PME
115
110%
US
Inspire Medical Systems Inc
NYSE:INSP
Negative Multiple: -167.4 N/A
US
Doximity Inc
NYSE:DOCS
23.4
116%
SE
Sectra AB
STO:SECT B
Negative Multiple: -66.5 N/A
US
Evolent Health Inc
NYSE:EVH
279.1
2 086%
US
Goodrx Holdings Inc
NASDAQ:GDRX
Negative Multiple: -110.7 N/A

See Also

Summary
CGS intrinsic value, competitors valuation, and company profile.
DCF Valuation
CGS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CGS stock valuation using valuation multiples.
Wall Street Estimates
CGS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CGS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 132,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.